Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan

Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy

New Gene Therapy for Cancer Offers Hope to Those With No Options Left

Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy

Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors

Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch Receptor to Treat Cancer and other Diseases

Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel

UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors

UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option

Capricor Therapeutics Announces Private Placement of Common Stock

Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

UroGen Pharma Welcomes New Board Member Kate Falberg

Sienna Biopharmaceuticals Announces $40 Million Series B Financing

Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer

Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors

Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy